BriaCell Therapeutics reports significantly higher PFS for its top responder patient in the Phase 2 study of BriaCell’s Bria-IMT regimen in combination with an immune checkpoint inhibitor in metastatic breast cancer. The patient remains alive and she continues to receive BriaCell’s treatment regimen. The patient had a large right orbital lesion and a right temporal lobe lesion. The temporal lobe lesion is no longer detectable, while the orbital lesion has continued to shrink markedly. In addition, her tumor markers have markedly decreased from her pre-treatment levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer
- BriaCell Subsidiary BriaPro Releases Financial Reports
- BriaCell’s Bria-IMT™ Shows Promise for Breast Cancer
- BriaCell presents clinical efficacy data from Phase 2 Bria-IMT study
- BriaCell Presents Clinical Efficacy Data at ASCO 2024